Laboratory of Molecular Technology

分子技术实验室

• 批准号: 8429265
• 负责人: DAVID HEIMBROOK
• 金额: $ 406.99万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-26 至 2018-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8429265
• 关键词: Automation; Bioinformatics; Clinical; Collaborations; Communities; Contract Services; DNA Sequence; Data Analyses; Development; Diagnostic; Disease; Genes; Genetic; Genomics; Goals; Information Management; Laboratories; Lead; Messenger RNA; Molecular; Molecular Biology; Molecular Profiling; National Cancer Institute; Oligonucleotides; Pathway interactions; Proteins; Proteomics; Sampling; Services; Solutions; System; Technology; United States National Institutes of Health; genetic profiling; novel; organizational structure; prognostic; software development; technological innovation; tool; working group

The Laboratory of Molecular Technology (LMT) at the National Cancer Institute (NCI) - Frederick is an integrated, high-throughput molecular biology laboratory focusing on the development of genetics, genomics, and proteomics technologies together with associated laboratory automation systems, data analysis, and information management tools. A primary goal of LMT is to develop integrated strategies, using multiple technology platforms, that maximize the value of clinical samples and lead to the identification of pathways/ genes/gene products involved in the development of disease and the assembly of genetic or expression profiles (both mRNA and protein) for the identification of prognostic and diagnostic indicators. LMT is unique in that a variety of novel and highly advanced genomics/proteomics technology platforms are currently being utilized, integrated, and developed under a single laboratory director. This organizational structure allows for the integration of platforms, elimination of platform redundancy, and cooperative platform usage. Having a diverse set of groups working in close proximity provides the additional advantage of stimulating creative solutions and technological innovation. LMT offers its advanced technologies to the NCI and NIH communities via collaboration, contracts and services provided by its service laboratories as follows and further described in ¿LMT Services.¿ ¿ DNA Sequencing and Automation Laboratory ¿ Molecular Diagnostics Laboratory ¿ Affymetrix and Agilent Microarray Laboratory ¿ Oligonucleotide Synthesis Laboratory ¿ Bioinformatics and Software Development Laboratory ¿ Genomics Laboratory ¿ Quantitative PCR Laboratory

分子技术实验室（LMT）在国家癌症研究所（NCI）-弗雷德里克是一个综合的，高通量的分子生物学实验室，专注于遗传学，基因组学和蛋白质组学技术的发展，以及相关的实验室自动化系统，数据分析和信息管理工具。LMT的主要目标是使用多种技术平台开发综合策略，最大限度地提高临床样本的价值，并导致识别参与疾病发展的途径/基因/基因产物，以及用于识别预后和诊断指标的遗传或表达谱（mRNA和蛋白质）的组装。LMT的独特之处在于，目前正在利用各种新颖和高度先进的基因组学/蛋白质组学技术平台，并在一个实验室主任的领导下进行整合和开发。这种组织结构允许平台的集成、消除平台冗余以及协作平台使用。有一组不同的小组在附近工作提供了刺激创造性的解决方案和技术创新的额外优势。LMT通过其服务实验室提供的合作，合同和服务向NCI和NIH社区提供先进技术，如下所述，并在LMT服务中进一步描述。<$DNA测序和自动化实验室<$分子诊断实验室<$Affyoung和Agilent微阵列实验室<$寡核苷酸合成实验室<$生物信息学和软件开发实验室<$基因组学实验室<$定量PCR实验室